Enrupatinib clinical trials
Also written EI-1071.
How each study uses enrupatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enrupatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- EI-1071
- 2
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 0
Elixiron Immunotherapeutics Inc. (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test enrupatinib.
- Aug 2027A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy VolunteersPhase 1 · Elixiron Immunotherapeutics Inc.
Studies
Open first, then newest update. How each study uses enrupatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy VolunteersNot yet recruitingPhase 1Elixiron Immunotherapeutics Inc.NCT07903337Written as EI-1071
- A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease PatientsCompletedPhase 2Elixiron Immunotherapeutics Inc.NCT06745583Written as EI-1071 tablet, oral
- A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy VolunteersCompletedPhase 1Elixiron Immunotherapeutics Inc.NCT04238364Written as EI-1071
Codes
What other systems call enrupatinib · ClinicalTrials.gg INT015881
- UNII (FDA) 9L35RVQ9J6ENRUPATINIBOne source FDA
- NCI Thesaurus C211750EnrupatinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9L35RVQ9J6 | ENRUPATINIB | One source FDA |
| NCI Thesaurus | C211750 | Enrupatinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.